Metastasis and invasion occur in the majority of epithelial ovarian carcinoma at diagnosis. To delineate the molecular signature in ovarian cancer invasion, we established and characterized a human ovarian endometrioid carcinoma (EC) cell line OVTW59-P0 and its invasion-related sublines (P1-P4, in the order of increasing invasive activity). P4 showed faster migration and larger xenograft formation with metastasis than P0. By microarray analysis of different gene expression among P0-P4 sublines, one group of gene was found negatively correlated with cancer invasion. Among these genes, IGFBP-3 was identified as one of the most remarkably suppressed gene that showed lower gene expression in P4 than P0. Re-expression of IGFBP-3 in P4 effectively inhibited cell migration, invasion and metastasis, but did not affect cell proliferation. In 35 patients with EC tumors, low IGFBP-3 expression correlated clinically with higher tumor grade, advanced stage and poor survival. Our results provide evidence and indicate that IGFBP-3 plays an important role as an invasion-metastasis suppressor in ovarian EC.
Introduction
Epithelial ovarian cancer (EOC) is the most lethal gynecological cancer among women worldwide. Metastasis occurs in most patients at the time of diagnosis. Prognosis of EOC is poor due to high-subsequent recurrent rate after complete surgery and chemotherapy (Ohwada et al., 2001) . Survival is at about 3 years for patients with advanced EOC (McGuire et al., 1996) . The primary causes of cancer-treatment failure in ovarian cancer are due to the difficulty in early diagnosis and the detrimental process of invasion and metastasis.
Little is known about the cellular changes that correlate or determine the process of tumor cell invasion and metastasis in ovarian carcinoma. EOC is not like most of the gradually progressive diseases, such as breast, uterine cervix, colon and prostate cancer, having a welldefined preneoplastic component and a preinvasive component. Based on the morphological criteria, EOC are classified into four histological subtypes: serous, mucinous, endometrioid and clear cell. The endometrioid carcinoma (EC) subtype, which represents about 10 to 20% of EOC (Goodman et al., 2003) , has been suggested to arise from endometriosis and follow a model of progression through atypical proliferation to malignant tumors (Jiang et al., 1998; Bell and Kurman, 2000; Simpson and Bischoff, 2002) . To simulate and trace the process of ovarian cancer invasion, we established an ovarian EC cell line OVTW59 in this study. We then setup an ovarian cancer invasion model by selecting the OVTW59 sublines with progressive increase in invasion capabilities. The degree of invasiveness in these sublines was verified through an in vitro invasion assay and xenograft model. Using cDNA microarray analysis, several invasion-associated genes were selected and validated by quantitative reverse transcriptase-PCR. Among them, we demonstrated that insulin-like growth factor binding protein-3 (IGFBP-3) was a potential invasion suppressor gene.
The insulin-like growth factor (IGF) system is recognized for playing a variety of roles in the circulation, the extracellular and intracellular environment, and in tumorigenesis (Firth and Baxter, 2002) . IGFBPs are circulating transport proteins for IGF-I and IGF-II, and IGFBP-3 is the predominant IGFBP in circulation (Firth and Baxter, 2002; LeRoith and Roberts, 2003) . It is unclear whether IGFBP-3 might be directly involved in cancer invasion and metastasis. Here, through in vitro and in vivo invasion parameters, we demonstrated a novel role of IGFBP-3 in tumor invasion-migration. We correlated the importance of IGFBP-3 clinically with patients with EC tumors. Our results provided evidence that IGFBP-3 plays a potential role as an invasionmigration suppressor of human ovarian EC cells.
Results

Establishment and characterization of an ovarian EC cell line
The ovarian cancer cell line OVTW59 was derived from a high-grade EC. Microscopically, the original tissue revealed a high-grade glandular and cribriform structure with areas of squamous differentiation and moderate fibrous stroma containing less mononuclear cell infiltration ( Figure 1a ). OVTW59 grew well without interruption for more than 31 months and 250 serial passages. The monolayer-culture of OVTW59 cells showed a picture of spindle cell in shape with bipolar or tripolar process extension (Figure 1b ). In the confluent state, they arranged in pavement with multi-layering without contact inhibition. Ultrastructurally, these cells contained indented and lobulated nuclei with abundant secretary granules, mitochondria, tonofilaments and microvilli. Desmosome junctions appeared at adjacent cells ( Figure 1c ). These features indicate that OVTW59 is epithelial in origin. Other features of OVTW59 were shown in Supplement 1. By karyotyping, OVTW59 cells were heterogeneous in population. The average chromosomal number was 77 (Figure 1d ). In heterotransplantation, histopathology of OVTW59 xenograft tumors showed a poorly differentiated glandular and cribriform carcinoma with focal areas of squamous metaplasia and keratinization, and strong fibrous stroma with less mononuclear cell infiltration (Figure 1e ). Site of squamous metasplasia showed prominent vimentin expression (Figure 1e , insert), confirming that OVTW59 belongs to the histopathological type of EC (McCluggage, 2002) .
Selection and establishment of the invasion-related sublines
The invasive sublines were selected from the OVTW59 cells (assigned as P0) through Matrigel-coated transwell membranes. Cells that had invaded through the Matrigel XXX, t(3; 22), t(6; 12), t(9; 19), t(15; 22) ,del(X)(q23),del(7)(q22). (e) Histopathological micrograph of the P0 xenograft demonstrating a poorly differentiated EC (H&E, Â 200). The inset shows vimentin expression at the area of squamous metaplasia with keratinization (arrow) ( Â 200).
IGFBP-3 as an invasion-metastasis suppressor P-L Torng et al were collected as P1, signifying one passage through the basement-membrane matrix. Subsequently, these cells were regrown and repeatedly passed three more times through the invasion-selection procedure. The cells harvested from each subsequent round of selection were designated as P2, P3 and P4, respectively. The selected P4 cells were smaller, less adhesive and more elongated with multiple polar processes comparing to P0. By karyotyping, P4 showed more chromosomal instability with an average chromosome number of 68 (Figure 2a ). Both P0 and P4 were consistent in having triploidy at chromosome X; a translocation between chromosomes 3 and 22, and chromosomes 15 and 22; and a deletion of chromosome 7 at q22. Growth curves were examined and the cells grew logarithmically 2 days after subculture. P1, P2, P3 and P4 grew slightly faster than P0 with a decrease in doubling time from 26 to 19 h (Figure 2b) , and an increase of saturation density from 5 Â 10 6 to 10 Â 10 6 cells per cm 3 after 8 day's culture.
Establishment of invasion model with progressive increase in invasion and metastasis
The invasiveness of the parental P0 and each sublines, P1-P4, was studied by the membrane invasion culture system (MICS) (Hendrix et al., 1987) . P2 showed a twofold and P4 a three-fold increase of invasive ability than P0 (both Po0.05) (Figure 2c ). Therefore, OVTW59 P0 to P4 cells represented an ovarian cell line model with increasing invasiveness. Furthermore, a significant increase in MMP-2 levels from P0 to P4 was found by immunoassay. The concentration of pro-MMP-2 was 7 Â higher in P4 than P0, while the active MMP-2 was increased 150 Â higher in P4 than in P0 (Figure 2d ). Similar changes were confirmed in western blot analysis. Heterotransplantation was used as an in vivo tumorigenic parameter to study the degree of tumor invasion and metastasis in the parental P0 and its subline P4. Five severe combined immunodeficiency (SCID) mice were used in each group and tumor nodule developed in all of the transplanted mice. In P0, the latency period of tumor growth was 3-4 weeks and a maximum growth to a diameter of 12-15 mm was seen at 5-6th weeks. Tumor growth attenuated at about 1.5 cm in diameter with central ulceration at the 35th day. In P4, all xenograft tumors continued to grow into multiple nodules without ulceration at the 60th day, and on average was six-fold larger than P0 xenografts ( Figure 2e ). The subcutaneous tumors of P4 xenografts were more anaplastic with numerous mitotic figures. Metastasis condition was observed by gross observation of each organ after autopsy and by microscopic examination of tissue sections from all visceral organs. No visible metastatic lesions were found in all of the five P0 xenografts. In P4, metastasis occurred in four out of five xenografts (four into pleural cavities and one into liver and pelvic cavity, including uterus, fallopian tubes and ovaries).
We first used CA-125 to assess cancer invasion. Levels of CA-125 increased during the establishment of cell line, but remained stable among P0-P4 cells (Figure 2f ). This result indicates that CA-125 cannot serve as a good marker for ovarian cancer invasion. Other novel markers indicating tumor invasion are imperative for clinical investigation. Therefore, microarray analysis was performed among P0-P4 cells.
Gene expression patterns of positive or negative correlation with invasiveness By cDNA microarray analysis, we identified two clusters of genes selected in accordance positively and negatively correlated with the increasing invasion capability of P0-P4 with specific thresholds as reference to the empirical invasion abilities of the cell lines as shown in Figure 2 . The dendrograms of genes correlated positively or negatively with invasion was shown in Supplement 3. Supplement 4 showed a list of the top 25 positively and 25 negatively correlated genes and their microarray data.
We surveyed the gene-ontology (GO) differences between these two clusters of invasion correlated genes and delineated their differential difference in functions using a web-interface program (FatiGO; http://fatigo. bioinfo.cnio.es/; (Al-Shahrour et al., 2004) ). Clusters of invasion correlated genes according to their 'Biological Process' GO terms were shown in Supplement 5. A total of 39 genes were randomly selected from the GO-term, primarily involved in cell proliferation and signal transduction, for QRT-PCR and compared with the microarray data ( Figure 3 ). About 85-90% similarity was demonstrated. A list of primers used for QRT-PCR was shown in Supplement 6.
Suppression of cancer cell migration, invasion and metastasis, but not cell proliferation by IGFBP-3 By simulating and tracing with ovarian cancer invasion, we identified IGFBP-3 as a most significant negatively correlated gene. In QRT-PCR analysis, P4 showed very weak IGFBP-3 gene expression when compared with P0. Similarly, western blot analysis showed very weak 43 kDa band of IGFBP-3 in P2 and P4, while P0 and P1 revealed stronger IGFBP-3 (Figure 4a ). To determine the functional role of IGFBP-3 in ovarian cancer cells, P0 and P4 were stably transfected with either the pK vector (ÀV) or the constitutively expression vector containing hIGFBP-3 (ÀI). By scratch assay, P4 had higher migration ability than P0 (Figure 4b , lanes 1 and 2). Re-expression of IGFBP-3 in P4 (P4-I) reduced the migration ability to nearly the same level as in P0 (Figure 4b , lane 6). Furthermore, when IGFBP-3 expression in P4-I (IGFBP-3 stable transfectant) was suppressed by siRNA, we found the resuming of migration activity ( Figure 4b , lane 8 comparing to lane 7; IGFBP-3 siRNA versus control transfection with scrambled oligo-RNA).
In heterotransplantation experiment, similar to the P4 and P0 xenografts, tumor mass in P4-V was significantly larger than that in P4-I (Figure 4c ). In P4-I, tumor growth attenuated with central necrosis and marked apoptosis at around 60 days (Figure 4d ). Metastasis occurred in all P4-V xenografts (all five into pleural cavities and one into liver and mesentery) (Figure 4e ), but none in the P4-I xenografts. Histopathology of the primary xenografts and the metastatic tumors were similar to that of the P4 tumors.
The prognostic role of IGFBP-3 expression for patient survival A total of 35 cases of EC were recruited and the average age of these patients was 49.4 ± 13. 2 years old, where 42.8% were in the advanced stage (stages 3 and 4) and 62.9% were at higher grade (grades 2 and 3) ( Table 1) . By immunostaining, IGFBP-3 was localized to the cytoplasm in most tumor cells and was strongly expressed in tumors of lower grade (Figure 5aG1 ) but weakly in higher grade tumors (Figure 5aG3) .
Expression of IGFBP-3 was significantly associated with earlier International Federation of Gynaecology and Obstetrics stage and lower tumor grades. Tumor recurrence was significantly associated with stage, tumor grade and IGFBP-3 expression (Table 1) . The mean survival time of these patients was 36.1±1.9 months and the recurrence-free survival was 23.4±1.5 months. The 3-year overall survival rate was 73.2% (94.1 versus 57.8% for high versus low IGFBP-3 expressions) and the 3-year recurrence-free survival rate was 61.3% (82.3 versus 35.0% for high versus low IGFBP-3 expressions). By Kaplan-Meier survival analysis, patients with low IGFBP-3 expression had significantly lower recurrencefree and overall survivals (Figures 5b and c) . Using Cox proportional hazard regression analysis, low IGFBP-3 expression correlated significantly with lower recurrence-free and overall survivals, even after age, but not stage and grade adjustment. However, IGFBP-3 was not related to patient survivals in multivariate analysis. In stepwise selection, stage was the maximum likelihood estimate of recurrence-free survival, and IGFBP-3 expression for the estimate of overall patient survival ( Table 2) .
Discussion
The direct causal relationship between the IGF system and ovarian cancer progression in patients is lacking. We demonstrated for the first time that IGFBP-3 is directly involved in the suppression of cancer invasion Figure 3 Validation of the gene expression profiles by QRT-PCR. Gene expression profiling of selected upper 5% (higher than 3 Â ) positively and lower 5% (less than 3 Â ) negatively correlated genes from normalized microarray data (lanes 1-4) of P0-P4. A total of 39 genes were selected randomly from microarray data and validated for their gene expression using QRT-PCR. QRT-PCR analysis (lanes 5-8) showed the differentially gene expression with increasing invasiveness from P0 to P4. Figure 2e ; P ¼ 0.067 between P0 and P4; P ¼ 0.029 between P4-I and P4-V; by paired t-test). Immunohistochemical staining of P4-I xenograft showing tumor necrosis and apoptosis (arrow heads) in the central part of tumor (d1) ( Â 100) and near the skin surface (d2) ( Â 200) (H&E). Metastasis of tumor (arrows) into liver (e1) and lung (e2) in P4-V xenografts (H&E) (both Â 100).
IGFBP-3 as an invasion-metastasis suppressor P-L Torng et al
IGFBP-3 as an invasion-metastasis suppressor P-L Torng et al and metastasis in ovarian EC. By in vitro and in vivo invasion parameters, we showed that the expression of IGFBP-3 is negatively correlated with cancer invasion/ metastasis. This loss of IGFBP-3 expression is correlated in line with patient survival.
Histological subtypes of EOC were commonly not discriminated in studies reporting the clinical significance of IGFBP-3 in ovarian cancer. Lower tissue IGFBP-3 expression was reported in associated with increased risk of disease progression and with higher Moreover, we demonstrated in vitro and in animal study that IGFBP-3 is involved in the regulation of ovarian cancer invasion and metastasis. The ovarian EC cell line OVTW59 (P0) appeared as a mixed combination of different clones that were predominately less invasive. More invasive clones (P1-P4) were repetitively selected through Matrigel. We found IGFBP-3, selected from this invasion model by cDNA microarray analysis, negatively associated with tumor invasion (Figure 2) . By re-expression of IGFBP-3, tumor migration and metastasis were again inhibited in in vitro and in vivo studies (Figure 4) . Furthermore, by using siRNA to suppress IGFBP-3 expression in the stable IGFBP-3 P4 transfectants (P4-I), we found the resuming of migration activity (Figure 4b ). These results showed evidence that IGFBP-3 plays a direct role in the regulation of EC cell migration, invasion and metastasis. However, when we suppressed IGFBP-3 using siRNA in the low migration capability P0 cells, we did not find the acceleration of tumor migration (data not shown). It seems that though IGFBP-3 could suppress migration in the high-invasive P4, it was insufficient to enhance cell migration in the low invasive P0. It is probably that other genes, such as those that we have identified from the microarray study, might be necessary to act coordinately with IGFBP-3 to accelerate cell migration. Kang et al. (2003) has reported a similar finding in their study in genes mediating in breast cancer metastasis.
The association of IGF family with patient survival is not universal in different cancer patients. In ovarian EOC, higher IGF-II expression is the only gene reported significantly associated with poor patient survival and higher disease progression (Sayer et al., 2005; Lu et al., 2006) . IGF-II was found higher in the serous subtype (Sayer et al., 2005; Lu et al., 2006) , while IGFBP-3 is more frequently expressed in the nonserous subtypes of EOC (LU et al., 2006) . We studied the IGFBP-3 expression and cell migration activities in some cell lines derived from nasopharyngeal, gastric, prostate and lung cancers, but did not find a similar anti-migration effect of IGFBP-3 (data not shown). Recently, Oh et al. (2006b) reported an antimetastatic activity of IGFBP-3 in two non-small cell lung cancer (NSCLC) cell lines. These suggested that the migration-invasion suppressor role of IGFBP-3 is a unique phenomenon to some tissues or cell lines. And so far, our study is the second after Oh et al. to document a direct correlation between IGFBP-3 and cancer invasion.
IGFBP-3 can inhibit cell proliferation and induce apoptosis through IGF-dependent or -independent effects (Firth and Baxter, 2002; LeRoith and Roberts, 2003) . In our study, both antiproliferation and apoptosis effects of IGFBP-3 were found in in vivo studies, but we observed no such effects in in vitro studies. Both P0 and P4 showed nearly similar rates in cell proliferation (Figure 2b ). And by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenol tetrazalium (MTT) assay, we observed no difference in cell survival rates among P0, P4 and their transfectants that showed different levels of IGFBP-3 expression (data not shown). In the xenograft model, P0 and P4 xenograft masses were similar in size before day 35. However, growth attenuated with tumor necrosis and apoptosis occurred in P0 xenograft after day 35 and in P4-I xenografts after day 60 (Figures 4c and d) . In P4 and P4-V xenografts, no attenuation of growth was observed. Instead, tumor masses grew significantly larger than the xenograft masses of P0 and P4-I, respectively. It is possible that the apoptosis that we observed in the in vitro system could be due to the effect of IGFBP-3 as a modulator to other paracrine or autocrine factors (Mishra and Murphy, 2004) . For example, IGFBP-3 could mediate its anti-tumor effect through the regulation of angiogenesis (Oh et al., 2006a) . But, we observed no difference in the microvessel counts in P0 and P4 xenograft tumors. We also detected no difference in the expression of angiogenesisrelated proteins, such as vascular endothelial growth factor and basic fibroblast growth factor in P0 and P4 cells (both data not shown). It is unlikely that regulation through angiogenesis is the cause of anti-metastasis effect of IGFBP-3 in our in vitro system. More studies are required to elucidate further on any other possible modulator effects of IGFBP-3. Nevertheless, we observed multiple metastasis in P4 and P4-V xenograft masses (Figure 4e ), but no micro-metastasis with P0 or P4-I xenograft tumors at the time of sacrifice. Our findings suggested and supported the anti-invasion/ metastasis, in addition to the known antiproliferation and apoptosis effects of IGFBP-3.
Recently, Silha et al. (2006) reported a reduction in tumor growth in an IGF-independent IGFBP-3 transgenic model. In our study, we detected no IGF-1 in all sublines by enzyme-linked immunosorbent (ELISA) study. When we inhibited IGF-1 using IGF-1R antibodies, we found no influences in the invasion activities of P0 and P4 (data not shown). (IGF-II effect was undetermined). These results suggested that the invasion suppressor effect of IGFBP-3 is IGF-1 independent. The antimetastatic activity of IGFBP-3 in NSCLC reported by Oh et al. was found mediated through IGFdependent MMP-2 and IGF-independent urokinasetype plasminogen activator (uPA) pathways (Oh et al., 2006b) . In our study, we found increasing MMP-2 levels among the sublines (Figure 2d ), but no difference among the P0 and P4 IGFBP-3 transfectants (data not shown). We also found no differences in the uPA expression among the sublines and the IGFBP-3 transfectants (data not shown). This suggested that IGFBP-3 as a tumor migration, invasion and metastasis suppressor in ovarian EC is IGF-1 independent and is probably different from that in NSCLC. The exact mechanism of IGFBP-3 on invasion suppression in ovarian EC needs further elucidation.
The identification of IGFBP-3 as an invasionsuppressor gene in our study was based on microarray analysis. Our promising result suggested that other target genes that we have identified correlated with invasion are useful to unravel the cell signature changes that occurred in concert with ovarian cancer metastasis. Furthermore, we demonstrated that IGFBP-3 is a prognostic marker for ovarian EC such that it is suppressed in high-grade carcinoma and correlated significantly with survival in patients with ovarian EC. Our results provide evidence that IGFBP-3 plays an important role as an invasion-metastasis suppressor in ovarian EC.
Materials and methods
Chemical reagents
Cell culture reagents were purchased from Gibco/BRL (Grand Island, NY, USA) and general laboratory reagents were purchased from Sigma-Aldrich (St. Louis, MO, USA) unless otherwise specified.
Establishment of the ovarian EC cell line
The ovarian EC cell line (OVTW59) was derived from a 63-year-old woman with ovarian EC at stage IIIc. Tumor tissue fragments were obtained from ovarian specimen during debulking surgery in September 1997. The procedure for establishment of the ovarian EC cell line was performed according to our previously published method (Lin et al., 1993) . The cell line was maintained in Dulbecco's modified Eagle's media (DMEM) solution with 10% fetal calf serum (FCS). Fibroblasts were removed gradually from subsequent culture. Absence of mycoplasma contamination was confirmed using a Gene-probe rapid-detection system (Gene-probe, San Diego, CA, USA) and by electron microscopy.
Characterization of the ovarian EC cell line Ultrastructural Study Cells were grown on telflon-coated coverslip, fixed in 2.5%. glutaraldehyde in 0.1 M phosphatebuffered saline (PBS), pH 7.4, containing 8.5% sucrose and 0.002% CaCl 2 and then processed for electron microscopic observation (Lin et al., 1993) .
Cytogenetic analysis
Cells were grown to log phase and 0.03 mg ml À1 colcemid was added for 30 min. The mitotic cells were harvested by a shakeoff method. After centrifugation, the pellet was resuspended in cold 0.075 M KCL hypotonic solution for 20 min and then fixed in methanol: acetic acid (3:1) solution. Cells were dropped from about 60 cm high onto a cold glass slide and air-dried. Chromosomes were stained with Giemsa, air-dried and mounted with Permount for light microscopic analysis. The average chromosome number was counted from 100 mitotic cells and karyotypic analyses were performed.
Growth characteristics
Cells at 1 Â 10 4 with 3 ml of DMEM containing 5% FCS were placed in 6-well plates in triplicate. The cells were harvested at 12-h intervals until the 8th day, and cell numbers were counted using a hemocytometer.
CA1-25 analysis 1 Â 10 6 of cells were seeded in culture flask with 10 ml of DMEM without FCS for 24 h. Culture medium was collected for CA-125 (Abbott Laboratory, Illinois, USA), measurements by Immulite 2000.
Establishment of invasion-related sublines by invasion chamber
Subpopulations from OVTW59 cells were selected according to their differential invasiveness, using transwell plates (Chu et al., 1997) . Briefly, the polycarbonate membranes (containing 8 mm pores) of the transwell inserts were coated with a reconstituted basement-membrane gel (matrigel) (Collaborative Research, Bedford, MA, USA). Cells were suspended in DMEM with 5% FCS, seeded and incubated for 72 h at 37 1C. The inserts were removed and cells that migrated through the membranes and attached to the lower-chamber compartments were harvested aseptically and expanded for second-round selection. The original cell line at 100th passage, which did not pass through membrane barriers, was designated as P0. The subline of the first-round selection was designated as P1, and sublines from 2, 3 and 4 rounds of selection were designated as P2, P3 and P4, respectively.
In vitro invasion assay
The MICS (Hendrix et al., 1987) was used with some modification. A polycarbonate membrane, containing 10 mm pores, (Nucleopore Corp., Pleasanton, CA, USA) was coated with a mixture of 50 mg ml À1 laminin, 50 mg ml À1 type IV collagen and 2 mg ml À1 gelatin (BioRad, Hercules, CA, USA) in 10 mM glacial acetic acid solution. The membrane was placed between the upper-and lower-well plates of the MICS chamber. Cells at 5 Â 10 4 were resuspended in DMEM containing 10% FCS and seeded into the upper well of the chamber. After incubation at 37 1C for 36 h, cells that had invaded the coated membrane through the membrane pores were removed from the lower wells with 1 mM ethylene diamine tetraacetate in PBS, and dot-blotted on a 3 mm polycarbonate membrane. Blotted cells were fixed in methanol, stained with Liu's staining solution (Handsel Technologies Inc., Taiwan) and the cell number was counted under microscope.
MMP-2 activity assay
The Biotrak MMP-2 activity assay system (Amersham Pharmacia Biotech, NJ, USA) was used as manufacturer's illustrations. Modified urokinase activated by captured active MMP-2 into an active detection enzyme through a single proteolytic event was used. P-aminophenylmercuric acetate was either added to detect the total MMP-2 ('pro'-form) or neglected to measure the endogenous free active MMP-2. Reaction products of the chromogenic S-2444 peptide substrate were read by microtiter plate spectrophotometer at 405 nm. Tumorigenicity SCID mice, age 6-8 weeks were transplanted subcutaneously in the back with 2 Â 10 7 cells. Size of tumor growth was measured using vernier calipers. Tumor volume was calculated by the formula, length Â width 2 Â 0.52, which approximates the volume of an elliptical solid mass. Finally, the mice were autopsied for examination of visceral metastasis.
cDNA microarray analysis of differential gene expression among P0 to P4 Total RNAs were extracted using the RNeasy RNA extraction kit with DNase I treatment, and then reverse-transcribed with Superscript II Rnase H-reverse transcriptase (Invitrogen, Carlsbad, CA, USA) to generate Cy3-and Cy5-labeled cDNA targets for control (a universal common reference of RNAs stated in Supplement 1) and experimental samples (each cell line), respectively, according to the manufacturer's instructions. The labeled targets were hybridized on commercial 7.6 K cDNA microarrays representing approximately 7500 distinct human transcripts (Egenomix Human UniversoChip 8K; Egenomix Technology Corporation, Taipei) with detail description reported earlier (Juan et al., 2002) .
Quantitative real-time reverse-transcriptase PCR (QRT-PCR)
The primer sequences were designed by primer Express Software (Applied Biosystems, Foster City, CA, USA) (Supplement 6) and QRT-PCR was performed according to the manufacturer's instruction. Total RNA (2 mg) from each cell line was subjected to reverse transcription by Thermoscript RT-PCR system (Invitrogen, Carlsbad, CA, USA). The Q-PCR was performed with 4 ml of 200 Â diluted cDNA product, 5 ml of 2 Â SYBR Green Master Mixture, 0.5 ml of both 6 mM PCR forward primer and reverse primer (with the final reaction concentrations of 300 nM), respectively, in 10 ml of Q-PCR reaction mixture. The Rn-value was obtained from the PCR amplification curve to calculate the relative copy number of mRNA. The GAPDH mRNA was used as an internal control for comparison to normalize the data. A melting curve was used to identify a temperature where only the amplicon, and not the primer dimmers, counted for the SYBR green-bound fluorescence. Assays were performed in triplicate with Applied Biosystem model 7700 instruments.
Western blot analysis
Procedure of western blot analysis was described in Supplement 7.
Transfections
Transfections were carried out using lipofectamin 2000 (Invitrogen) according to the manufacturer's instruction. The constitutive expression vector, pKIGFBP-3, containing the full-length coding sequence of the hIGFBP-3 cDNA under the control of the hb-actin promoter, and the SV2-neo selection gene (containing resistance to G418) was used as previously described (Valentinis et al., 1995) . The pK plasmid without hIGFBP-3 insert was used as control. IGFBP-3 siRNA and scrambled oligo-RNA as control were obtained from Ambion Inc. (Austin, TX, USA). Stable lines were selected and established in DMEM solution with 10% FCS and 300 mg ml À1 G418 (Calbiochem, Darmstadt, Germany).
Scratch assay
Confluent monolayers of cells or transfectants were maintained in culture medium for 24 h. 200 ml plastic pipette tips were used to scratch the monolayer. After 17 h, transfectants were photographed under an inverted microscope.
MTT colorimetric assay Cells were seeded in 96-well flat-bottom tissue culture plates (2000 cells per well in 0.1 ml. culture medium) and incubated for 48 h. Cell survival rates were analysed by adding 0.5 ml of MTT at the concentration of 2 mg ml À1 to each well and incubated for 2.5 h. Supernatants were aspirated and the blue crystals formations were dissolved in 0.15 ml dimethyl sulfoxide solution and assessed by enzyme-linked immunosorbent assay reader at 540 nm.
Immunohistochemical staining A total of 35 cases of ovarian EC paraffin blocks were retrieved from National Taiwan University Hospital from year 1994 to 2000. These cases received surgeries and chemotherapies according to our previous report (Torng et al., 2004) . Procedure of immunohistochemical staining was listed in Supplement 8.
Statistical analysis
Statistical analyses for in vitro invasion assay and MMP-2 activities in OVTW59 sublines were performed using one-way analysis of variance. Paired t-test was performed for xenograft growth. Chi-square test or Fisher's exact test were used to correlate the IGFBP-3 expression patterns and the clinicopathological features in patients with ovarian EC. The associations of IGFBP-3 expressions with patient recurrencefree and overall survival rates were assessed by Kaplan-Meier analysis and the differences were tested for significance by the log-rank test. Cox proportional hazard regression analysis was used to evaluate the relationships of low IGFBP-3 expression with survival rates, including age, stage and tumor grade. A forward stepwise manner with the log-likelihood ratio significance test was used to select variables with maximum likelihood of patient survival. Probability values less than 0.05 were regarded as significant.
